SMS Pharmaceuticals reports robust Q2FY24 operational performance
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23
The collaboration brings a seamless digital experience to more formulators worldwide
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Total transaction value of the divestment is Rs. 3,660 million
PhytoSquene now available for clinical and commercial use
Lack of technology transfer stands out as a formidable barrier
This product will be manufactured at Lupin’s Pithampur facility in India
Gland Pharma has reported total income of Rs. 1426.57 crores during the period ended September 30, 2023
Subscribe To Our Newsletter & Stay Updated